OneMedNet Corp filings document the public-company reporting record for a healthcare data business with common stock and redeemable warrants. Recent 8-K reports cover Nasdaq continued-listing matters, including minimum bid price and market-value compliance notices, along with other material events affecting the company’s public listing status.
Proxy materials describe annual meeting procedures, stockholder voting matters, board composition, and governance disclosures. The filing record also identifies the company’s capital securities, including common stock and redeemable warrants exercisable for common shares, and records director-related governance updates through current reports.
OneMedNet Corp. (ONMD) regained compliance with Nasdaq’s $1.00 minimum bid price requirement after Nasdaq staff confirmed the common stock’s closing bid price was at least $1.00 per share for 10 consecutive business days, from September 29, 2026 through October 12, 2026. Nasdaq’s notice, received October 13, 2026, states that the matter is closed.
The company had received a notice of noncompliance on April 14, 2026, with a grace period until October 12, 2026 to regain compliance.
OneMedNet Corp (ONMD) director and 10% owner Thomas Kosasa purchased 129,758 common shares directly on October 7, 2026, at $5.78 per share. OneMedNet entered into a subscription agreement with Kosasa for a $750,000 investment. His reported direct holdings after the purchase were 1,983,573 shares; no Rule 10b5-1 plan is reported.
OneMedNet Corp’s Chief Medical Officer, director and 10% owner Jeffrey Yu purchased 45,126 common shares on October 9, 2026, through a subscription agreement for a $250,000 investment. The shares were valued at $5.54 per share, based on the issuer’s volume-weighted average price for the 10 trading days immediately before the purchase. Yu directly held 896,840 shares after the purchase. Separately, a trust for his children held 131,197 shares with an independent trustee; Yu said he had no investment control and disclaimed beneficial ownership. No Rule 10b5-1 plan is reported.
OneMedNet Corp (ONMD) Chief Financial Officer and director Robert Lawrence Golden reported direct grants of 35,000 restricted stock units on July 6, 2026, and 10,000 restricted stock units on January 1, 2026. The January award amount reflects the 1-for-10 reverse stock split on September 29, 2026. The July grant vests in installments subject to continued service; the January grant vests in full on December 31, 2026, subject to the Consulting Agreement terms.
Golden also reported direct sales of 8,500 common shares to cover tax obligations upon RSU vesting and settlement: 2,500 shares at $6.6000 per share on September 14, 3,000 at $6.3000 on September 15, and 3,000 at $6.6300 on September 21, 2026. No Rule 10b5-1 plan is reported.
OneMedNet Corp reported that its Chief Executive Officer and director, Aaron Green, was granted 65,000 restricted stock units on July 6, 2026, under its 2022 Equity Incentive Plan. Green sold 5,000 common shares at $7.3920 per share on September 22 and 1,667 at $6.4800 per share on September 24, 2026, to cover tax obligations upon RSU vesting and settlement; no Rule 10b5-1 plan is reported. The share amounts and prices reflect the issuer's 1-for-10 reverse stock split on September 29, 2026.
OneMedNet Corp's prospectus supplement identifies up to 1,168,054 shares of common stock. It reports that a 1-for-10 reverse stock split took effect at 12:01 a.m. Eastern Time on September 29, 2026: each 10 issued and outstanding shares became one share. The company said the split was intended to bring ONMD into compliance with Nasdaq Capital Market's minimum bid price requirement.
The current report gives approximately 60,125,902 shares outstanding as of September 27, 2026, and approximately 6,012,591 after the split. A company press release separately gives approximately 59,286,450 shares outstanding as of September 24, 2026, and approximately 5,928,645 after the split. The split leaves the authorized share count, $0.0001 par value and voting rights unchanged; it proportionately adjusts equity plan shares and the shares and exercise prices underlying outstanding awards, warrants and other equity instruments. Fractional shares are rounded up to the nearest whole share.
OneMedNet Corp's prospectus covers a primary offering of up to 1,150,000 common shares and a secondary offering of up to 2,815,256 common shares; share information is adjusted for the reverse split.
The company implemented a 1-for-10 reverse stock split effective at 12:01 a.m. Eastern Time on September 29, 2026, following stockholder approval on September 18, 2026. Every 10 outstanding shares became one share, and fractional entitlements are rounded up. The authorized share count, par value and voting rights remain unchanged; equity awards, warrants and other equity instruments are proportionately adjusted under their terms. The company said the split was intended to bring it into compliance with Nasdaq Capital Market's minimum bid price requirement. Split-adjusted trading was expected to begin at market open under ONMD.
OneMedNet Corp. (ONMD) will implement a 1-for-10 reverse stock split effective at 12:01 a.m. Eastern Time on September 29, 2026; each 10 issued and outstanding common shares will become one share. The company says the split is intended to bring it into compliance with the Nasdaq Capital Market’s minimum bid price requirement.
The corporate-action description estimates outstanding shares will change from approximately 60,125,902 as of September 27, 2026, to approximately 6,012,591 after the split. The accompanying announcement separately gives approximately 59,286,450 shares as of September 24, 2026, and approximately 5,928,645 after the split. Fractional shares will be rounded up; authorized shares, par value and voting rights will not change.
OneMedNet Corporation (ONMD) stockholders approved an amendment to the Amended and Restated 2022 Equity Incentive Plan, increasing its authorized share count by 1,000,000 shares; the amendment became effective immediately upon approval. Stockholders also approved a charter amendment to effect a reverse stock split at a whole-number ratio from 1-for-5 to 1-for-20, with the ratio determined by the Board of Directors in its discretion.
At the September 18, 2026 annual meeting, stockholders elected Dr. Kenneth Alleyne, Sherry Coonse McCraw, and Dr. Jeffrey Yu as Class III directors for terms ending at the 2029 annual meeting, and ratified WithumSmith+Brown, PC as the independent registered public accounting firm for the year ending December 31, 2026. A total of 41,841,452 votes were represented in person or by proxy, equal to 70.57% of votes entitled to be cast and constituting a quorum.
OneMedNet Corp (ONMD) reported that Jeffrey Yu, a director, Chief Medical Officer and more-than-10% owner, entered into a subscription agreement to purchase 142,857 shares of common stock on September 10, 2026 for a $90,000 investment, valued at a $0.63 volume-weighted average price over the prior 10 trading days. Following this transaction, he holds 8,923,267 shares directly and an additional 1,311,970 shares are held indirectly in a trust for his children with an independent trustee; he disclaims beneficial ownership of the trust shares. No Rule 10b5-1 trading plan is reported.